Less than one in 10 people who could benefit from obesity jabs like Wegovy are able to get them, caution the global health agency as it publishes its inaugural guidance on the medications.
Considering in excess of 1,000,000,000 people worldwide currently obese, it is advocating for increased and just access to these injectable treatments.
Per forecasts, in excess of 2,000,000,000 could be living with obesity by 2030 if no action is taken.
"The latest guidelines acknowledges that excess weight is a lifelong illness that can be treated with comprehensive and lifelong support," stated its chief Tedros Adhanom Ghebreyesus.
Significant expense, limited production capacity, and supply-chain constraints are key hurdles to broad availability to the jabs that can aid individuals in losing significant weight, says the organization.
Skinny Jab Scarcity
Despite the present most favorable case, the manufacturing of these medications would only suffice for approximately 100 million people – less than 10% of the global need, per the health organization.
The recommendation urges countries and companies to expand access, by measures including voluntary licensing.
A patent on the active ingredient – the primary ingredient of the drug Wegovy – is due to expire in multiple countries in 2026.
How Weight-Loss Injections Function
These medications mimick a natural hormone to delay gastric emptying, suppress the appetite and boost the sense of being full so users reduce food intake.
People typically start to lose weight after several weeks of starting on the weekly injections.
Evidence suggests users may put most of the weight back on a year later of halting the medication, as their usual food cravings come back.
Being carrying excess weight increases your likelihood for experiencing medical conditions, including type 2 diabetes, heart disease, brain attack, and certain malignancies.
Excess weight concerns people in all nations and was responsible for millions of fatalities worldwide in 2024, according to the WHO.
